UBS Group AG Trims Stock Holdings in Sana Biotechnology, Inc. $SANA

UBS Group AG trimmed its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 18.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,182,958 shares of the company’s stock after selling 261,028 shares during the period. UBS Group AG owned 0.44% of Sana Biotechnology worth $4,815,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Baillie Gifford & Co. grew its stake in Sana Biotechnology by 13.6% in the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after purchasing an additional 1,371,775 shares during the period. Vanguard Group Inc. grew its stake in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after acquiring an additional 1,375,029 shares during the last quarter. Integral Health Asset Management LLC grew its stake in shares of Sana Biotechnology by 33.3% in the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $7,100,000 after acquiring an additional 500,000 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Sana Biotechnology by 103.1% in the third quarter. Millennium Management LLC now owns 1,620,000 shares of the company’s stock worth $5,751,000 after acquiring an additional 822,423 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Stock Performance

SANA stock opened at $3.15 on Friday. Sana Biotechnology, Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $6.55. The business’s 50-day moving average is $3.24 and its two-hundred day moving average is $3.89. The company has a market cap of $876.61 million, a price-to-earnings ratio of -3.39 and a beta of 2.17.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. Equities analysts predict that Sana Biotechnology, Inc. will post -0.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Morgan Stanley reaffirmed an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. Wedbush upped their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Rodman & Renshaw initiated coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.